<DOC>
	<DOCNO>NCT01523184</DOCNO>
	<brief_summary>This single-center , randomize , parallel group , multiple dose administration , double-blind , placebo-controlled study evaluate effect YKP10811 gastric , small bowel , colonic transit patient Chronic Constipation Functional Constipation . Four group include placebo group enrol receive multiple oral dos YKP10811 match placebo .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Pharmacodynamics YKP10811 Patients With Chronic Functional Constipation</brief_title>
	<detailed_description>If participant fulfills initial eligibility criterion , patient randomize 1 active treatment group placebo . During treatment period , patient receive study medication daily 8 day . Patients undergo scintigraphic assessment gastric , small bowel colonic transit solid 48-hour period . Patients male female , 18 65 year age body mass index ( BMI ) 19 40 kg/m2 , Chronic Constipation Functional Constipation evidence evacuation disorder assess Investigator meet inclusion criterion none exclusion criterion .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Nonsmokers ( refrain tobacco nicotine usage , include smokeless tobacco , nicotine patch , etc . ) least 6 month prior Day 1 study 2 . Body Mass Index 19 40 kg/m2 3 . Participants must willing follow dietary restriction 4 . Females childbearing potential ( ie , menopausal , hysterectomy , bilateral oophorectomy ) must complete negative pregnancy test ( urine ) prior receive radioisotope 5 . No evidence pelvic floor dysfunction 6 . If clinically indicate , absence evacuation disorder confirm within 30 day prior first dose study medication 7 . At Screening , patient must meet ROME III Criteria FC , assume absence structural biochemical explanation 8 . The patient 's screening ( baseline ) colonic transit test must show GC ≤ 2.4 24 hour ; 9 . Baseline EKG show QTc interval ≤ 450mSec 1 . History clinicallysignificant manifestation current abnormality organ system 2 . History inflammatory bowel disease 3 . Any history GI surgery within 6 month prior first dose study medication 4 . History clinicallysignificant prolong diarrhea , absence laxative 5 . Patients start special dietary habit and/or intense physical workout program within 4 week prior first dose study medication 6 . Any clinicallysignificant surgical procedure within 30 day prior first dose study medication 7 . History alcoholism drug addiction within 12 month prior first dose study medication 8 . Any patient acute illness within 5 day prior first dose study medication , eg , flu syndrome , GI virus , indigestion 9 . Patients breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Chronic constipation ( CC )</keyword>
	<keyword>Functional Constipation ( FC )</keyword>
	<keyword>Gastric Emptying</keyword>
	<keyword>Colon Transit</keyword>
	<keyword>multiple dos YKP10811</keyword>
	<keyword>gastrointestinal transit</keyword>
	<keyword>colonic transit</keyword>
</DOC>